Skip to main content

Table 1 Baseline characteristics of the development set and validation set

From: Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention

Measure

Development set

Validation set

P value

(n = 325)

(n = 138)

Clinical characteristics

Age, year, n (%)

  

0.579

 < 50

78 (24.0)

27 (19.6)

 

 50–70

195 (60.0)

88 (63.8)

 

 ≥ 70

52 (16.0)

23 (16.7)

 

Gender, n (%)

  

0.282

 Female

104 (32.0)

52 (37.7)

 

 Male

221 (68.0)

86 (62.3)

 

Presentation, n (%)

  

0.415

 STEMI with Urgent PCI

12 (3.7)

3 (2.2)

 

 STEMI with Delayed PCI

59 (18.2)

20 (14.5)

 

 NSTE-ACS

198 (60.9)

95 (68.8)

 

 SA

56 (17.2)

20 (14.5)

 

OMI, n (%)

  

0.381

 No

294 (90.5)

129 (93.5)

 

 Yes

31 (9.5)

9 (6.5)

 

Prior PCI, n (%)

  

0.616

 No

294 (90.5)

122 (88.4)

 

 Yes

31 (9.5)

16 (11.6)

 

Heart failure, n (%)

  

1

 No

286 (88.0)

121 (87.7)

 

 Yes

39 (12.0)

17 (12.3)

 

Atrial fibrillation, n (%)

  

0.288

 No

320 (98.5)

133 (96.4)

 

 Yes

5 (1.5)

5 (3.6)

 

Hypertension, n (%)

  

0.664

 No

169 (52.0)

68 (49.3)

 

 Yes

156 (48.0)

70 (50.7)

 

Diabetes mellitus, n (%)

  

0.815

 No

259 (79.7)

112 (81.2)

 

 Yes

66 (20.3)

26 (18.8)

 

Smoke, n (%)

  

0.496

 No

209 (64.3)

94 (68.1)

 

 Yes

116 (35.7)

44 (31.9)

 

Laboratory tests

Systolic BP, n (%)

  

0.749

 < 90 mmHg

92 (28.3)

44 (31.9)

 

 90–140 mmHg

181 (55.7)

68 (49.3)

 

 140–160 mmHg

40 (12.3)

20 (14.5)

 

 160–180 mmHg

11 (3.4)

5 (3.6)

 

 ≥ 180 mmHg

1 (0.3)

1 (0.7)

 

Diastolic BP, n (%)

  

0.76

 < 60 mmHg

18 (5.5)

6 (4.3)

 

 60–80 mmHg

143 (44.0)

65 (47.1)

 

 80–100 mmHg

150 (46.2)

59 (42.8)

 

 ≥ 100 mmHg

14 (4.3)

8 (5.8)

 

Glycemia, n (%)

  

0.837

 < 6.1 mmol/L

237 (72.9)

104 (75.4)

 

 6.1–11.1 mmol/L

79 (24.3)

30 (21.7)

 

 ≥ 11.1 mmol/L

9 (2.8)

4 (2.9)

 

Creatinine, n (%)

  

0.321

 < 110 mmol/L

313 (96.3)

136 (98.6)

 

 ≥ 110 mmol/L

12 (3.7)

2 (1.4)

 

Uric Acid, n (%)

  

1

 < 400 µmol/L

283 (87.1)

120 (87.0)

 

 ≥ 400 µmol/L

42 (12.9)

18 (13.0)

 

LDL-C, n (%)

  

0.06

 < 1.80 mmol/L

66 (20.3)

17 (12.3)

 

 1.80–3.63 mmol/L

220 (67.7)

96 (69.6)

 

 3.63–4.14 mmol/L

24 (7.4)

12 (8.7)

 

 ≥ 4.14 mmol/L

15 (4.6)

13 (9.4)

 

Lesion and procedure characteristics

Acute occlusion lesions, n (%)

  

0.645

 No

283 (87.1)

123 (89.1)

 

 Yes

42 (12.9)

15 (10.9)

 

Chronic total occlusions, n (%)

  

0.157

 No

294 (90.5)

131 (94.9)

 

 Yes

31 (9.5)

7 (5.1)

 

Ostial lesions, n (%)

  

0.646

 No

288 (88.6)

125 (90.6)

 

 Yes

37 (11.4)

13 (9.4)

 

Bifurcation lesions, n (%)

  

0.676

 No

257 (79.1)

106 (76.8)

 

 Yes

68 (20.9)

32 (23.2)

 

Restenotic lesions, n (%)

  

0.603

 No

316 (97.2)

136 (98.6)

 

 Yes

9 (2.8)

2 (1.4)

 

Location of stents, n (%)

LM, n (%)

  

1

 No

312 (96.0)

132 (95.7)

 

 Yes

13 (4.0)

6 (4.3)

 

LAD, n (%)

  

0.56

 No

84 (25.8)

40 (29.0)

 

 Yes

241 (74.2)

98 (71.0)

 

LCX, n (%)

  

0.413

 No

187 (57.5)

73 (52.9)

 

 Yes

138 (42.5)

65 (47.1)

 

RCA, n (%)

  

1

 No

198 (60.9)

84 (60.9)

 

 Yes

127 (39.1)

54 (39.1)

 

Number of treated vessels, n (%)

  

0.946

 1

177 (54.5)

73 (52.9)

 

 2

106 (32.6)

46 (33.3)

 

 3

42 (12.9)

19 (13.8)

 

Stent type, n (%)

  

0.157

 Sirolimus-eluting

213 (65.5)

87 (63.0)

 

 Paclitaxel-eluting

53 (16.3)

32 (23.2)

 

 > 1 type

59 (18.2)

19 (13.8)

 

Stent number, n (%)

  

0.785

 1

120 (36.9)

47 (34.1)

 

 2–3

143 (44.0)

67 (48.6)

 

 4–5

52 (16.0)

19 (13.8)

 

 ≥ 6

10 (3.1)

5 (3.6)

 

Total stent length, n (%)

  

0.407

 < 20 mm

49 (15.1)

21 (15.2)

 

 20–60 mm

165 (50.8)

69 (50.0)

 

 60–100 mm

73 (22.5)

38 (27.5)

 

 ≥ 100 mm

38 (11.7)

10 (7.2)

 

Stent diameter, n (%)

  

0.437

 < 3 mm

134 (41.2)

63 (45.7)

 

 ≥ 3 mm

191 (58.8)

75 (54.3)

 

Medications

Aspirin, n (%)

  

1

 No

1 (0.3)

1 (0.7)

 

 Yes

324 (99.7)

137 (99.3)

 

Clopidogrel, n (%)

  

0.235

 No

10 (3.1)

1 (0.7)

 

 Yes

315 (96.9)

137 (99.3)

 

Statins, n (%)

  

0.224

 No

20 (6.2)

4 (2.9)

 

 Yes

305 (93.8)

134 (97.1)

 

β-receptor blockers, n (%)

  

1

 No

89 (27.4)

38 (27.5)

 

 Yes

236 (72.6)

100 (72.5)

 

ACEIs/ARBs, n (%)

  

0.721

 No

162 (49.8)

72 (52.2)

 

 Yes

163 (50.2)

66 (47.8)

 

Calcium channel blockers, n (%)

  

0.593

 No

254 (78.2)

104 (75.4)

 

 Yes

71 (21.8)

34 (24.6)

 
  1. ACEIs, Angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BP, blood pressure; LM, left main stem; LAD, left anterior descending artery; LCX, left circumflex coronary artery; LDL-C, low-density lipoprotein-cholesterol; NSTE-ACS, non-ST elevation acute coronary syndromes; OMI, old myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-elevation myocardial infarction; SA, stable angina
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us